Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
Aileron Therapeutics, Inc. (ALRN)
Last aileron therapeutics, inc. earnings: 11/7 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aileronrx.com
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. Wanstall has served as the Company’s Vice President of Finance and Operations and principal accounting officer since 2018. “Rick has proven to be an invaluable member of our team, especially over the past few months since he assumed all financial responsibilities for the company. We are pleased to announce this well-deserved promotion,” said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. “This management team is well positioned to execute on the development strategy we have established for our lead compound ALRN-6924, a first-in-class dual MDM2/MDMX inhibitor. Our development program is led by two key clinical trials. The first is studying ALRN-6924 as a myelopreservation agent
Show less
Read more
Impact Snapshot
Event Time:
ALRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALRN alerts
High impacting Aileron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALRN
News
- Aileron Therapeutics to Present at Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics to Present at Two Upcoming Investor ConferencesGlobeNewswire
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionGlobeNewswire
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionGlobeNewswire
ALRN
Analyst Actions
- 4/18/24 - Ladenburg Thalmann
ALRN
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 8-K
- 5/1/24 - Form 424B5
- ALRN's page on the SEC website